HAVRIX INACTIVATED HEPATITIS A VACCINE

Full and emergency authorizations 2543416-58-4 DB16524 COVID-19(disease)SARS-CoV-2(virus) CasesDeaths JanuaryresponsesFebruaryresponsesMarchresponsesAprilresponsesMayresponsesJuneresponsesJulyresponsesAugustresponsesSeptemberresponsesOctoberresponsesNovemberresponsesDecemberresponses responses responses responses responses responses responses responses responses responses responses responses responses JanuaryresponsesFebruaryresponsesMarchresponsesAprilresponsesMayresponsesJuneresponsesJulyresponsesAugustresponsesSeptemberresponsesOctoberresponsesNovemberresponsesDecemberresponses responses responses responses responses responses responses responses responses responses responses responses responses JanuaryresponsesFebruaryresponsesMarchresponsesAprilresponsesMayresponsesJuneresponsesJulyresponsesAugustresponsesSeptemberresponsesOctoberresponsesNovemberDecember responses responses responses responses responses responses responses responses responses responses AfricaAntarcticaAsiaEuropeNorth AmericaOceaniaSouth America Cruise shipsNaval ships Endemic phaseEvacuationsFace masksInternational aidOriginLockdownsby countryMisinformationby governmentsFake treatmentsSocial distancingSoftwareTravelUnited NationsWorld Health OrganizationWTO IP waiverUndercounting of deathsCOVID-19 appsZero-COVID by country by governmentsFake treatments World Health Organization AfricaChinaEuropean UnionGermanyGhanaIndiaIrelandNetherlandsNew ZealandNigeriaPhilippinesRussiaSwedenUKgovernmentUSfederal governmentVietnam government federal government Disease testingBreathalyzerDevelopmentDrug developmentDrug repurposingPublic health mitigation BreathalyzerDevelopment HistoryResearchVITTDeploymentAuthorizationsOperation Warp SpeedMisinformation and hesitancyUSVaccine cardVaccine passports VITT US CoronaVacCovaxinConvideciaJanssenMedigenModernaNovavaxOxford–AstraZenecaPfizer–BioNTechSinopharm BIBPSputnik V AlphaBetaGammaDeltaOmicron EpsilonZetaEtaThetaIotaKappaLambdaMuCluster 5Lineage B.1.617 Arts and cultureAviationCannabisCinemafilmsDisneyFashionFinancial marketsFood industryFood securityJournalismMusicPerforming artsRetailShippingTelevisionUSsportscastingprogramsTourismVideo games films USsportscastingprograms sportscastingprograms CanadaIndiaIrelandMalaysiaNew ZealandRussiaUKUS Association footballBaseballBasketballCombat sportsCricketDisc golfGaelic gamesGridiron footballIce hockeyMotorsportRugby league Neurological and psychological symptomsPost-exertional malaise African diasporaIndian migrant workersAnimalsAlzheimer's disease patientsCrimeDeath rates by countryDisabilityDomestic violenceEmergency evacuationsEducationFemaleEnvironmentHospitalsLanguageLGBTQ communityLong-term careMedia coverageMental healthMigrationMilitaryNotable deathsOther health issuesPopular cultureProtestsPregnancyPrisonsReligionCatholic ChurchHajjScience and technologySocial mediaStrikesSuicidesTelehealthXenophobia and racism Female Catholic ChurchHajj DiplomacyInfected leadersIrelandMalaysiaNew ZealandRussiaUKUS vte Soberana 02orSoberana 2, technical nameFINLAY-FR-2,is aCOVID-19 vaccineproduced by theFinlay Institute, aCubanepidemiological research institute. The vaccine is known asPastoCovac(Persian:پاستوکووک) inIran, where it has been developed in collaboration with thePasteur Institute of Iran. It is aconjugate vaccinethat requires two doses, the second one being administered 28 days after the first shot.A third (booster) dose ofSoberana Plusmay also be given on day 56. It has received emergency use authorization in Iran in June 2021, and in Cuba in August 2021, where it has also been approved for children above 2 years old. The name of the vaccine, Soberana, is aSpanishword that means "sovereign".It followed a previous candidate vaccine called SOBERANA-01 (FINLAY-FR-1).